| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
9,581 |
8,386 |
$1.77M |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
7,852 |
6,634 |
$1.44M |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
3,235 |
2,899 |
$581K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
1,374 |
1,225 |
$299K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
1,842 |
1,539 |
$288K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
1,259 |
1,140 |
$253K |
| 70450 |
Computed tomography, head or brain; without contrast material |
1,520 |
1,303 |
$218K |
| G0378 |
Hospital observation service, per hour |
1,425 |
765 |
$161K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
339 |
329 |
$69K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
245 |
217 |
$43K |
| 93975 |
|
359 |
337 |
$37K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
1,576 |
1,401 |
$28K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
146 |
121 |
$19K |
| 76700 |
Ultrasound, abdominal, real time with image documentation; complete |
172 |
160 |
$19K |
| 80053 |
Comprehensive metabolic panel |
6,181 |
5,111 |
$18K |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
239 |
231 |
$16K |
| 76830 |
Ultrasound, transvaginal |
157 |
155 |
$15K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
4,231 |
3,189 |
$15K |
| 76805 |
Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation |
156 |
139 |
$13K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
69 |
64 |
$13K |
| 71046 |
Radiologic examination, chest; 2 views |
708 |
620 |
$13K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
5,101 |
4,248 |
$11K |
| 59025 |
Fetal non-stress test |
49 |
37 |
$10K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
5,398 |
4,200 |
$8K |
| 71045 |
Radiologic examination, chest; single view |
3,797 |
3,166 |
$8K |
| 85027 |
|
10,468 |
7,965 |
$7K |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
36 |
27 |
$7K |
| 70496 |
|
26 |
25 |
$6K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
155 |
130 |
$6K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
81 |
72 |
$5K |
| 84484 |
|
3,843 |
2,787 |
$4K |
| 80076 |
|
1,544 |
1,247 |
$3K |
| 86756 |
|
939 |
887 |
$3K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
42 |
39 |
$2K |
| 36415 |
Collection of venous blood by venipuncture |
1,082 |
812 |
$2K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
102 |
89 |
$2K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
639 |
574 |
$2K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
2,335 |
1,969 |
$2K |
| 73564 |
|
47 |
41 |
$2K |
| 87040 |
|
299 |
223 |
$2K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
5,269 |
3,985 |
$2K |
| 85610 |
|
1,965 |
1,547 |
$1K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
2,817 |
2,589 |
$1K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
27 |
26 |
$1K |
| 84703 |
|
2,521 |
2,208 |
$856.12 |
| 81003 |
|
1,431 |
1,304 |
$728.04 |
| 81001 |
|
3,071 |
2,600 |
$705.27 |
| 84443 |
Thyroid stimulating hormone (TSH) |
346 |
300 |
$695.95 |
| 83690 |
|
2,734 |
2,313 |
$691.87 |
| 85379 |
|
350 |
315 |
$684.89 |
| 83880 |
|
137 |
121 |
$571.30 |
| 86900 |
|
726 |
625 |
$550.89 |
| 73030 |
|
43 |
38 |
$532.54 |
| 86850 |
|
323 |
289 |
$482.25 |
| 72125 |
Computed tomography, cervical spine; without contrast material |
26 |
25 |
$458.84 |
| 83735 |
|
1,462 |
1,143 |
$448.06 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
3,092 |
2,444 |
$436.73 |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
2,296 |
2,119 |
$383.09 |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
3,839 |
3,485 |
$366.00 |
| 73610 |
|
44 |
43 |
$335.48 |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
629 |
551 |
$307.24 |
| 73130 |
|
25 |
25 |
$305.76 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
2,936 |
2,354 |
$296.94 |
| 87070 |
|
583 |
502 |
$244.89 |
| 73110 |
|
13 |
13 |
$244.02 |
| 85730 |
|
806 |
664 |
$239.46 |
| 73630 |
|
12 |
12 |
$225.78 |
| 86901 |
|
309 |
278 |
$209.38 |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
1,357 |
1,105 |
$196.65 |
| 74018 |
|
16 |
14 |
$134.62 |
| 81025 |
|
355 |
306 |
$113.33 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
1,416 |
1,184 |
$112.12 |
| 83605 |
|
194 |
140 |
$109.33 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
1,176 |
870 |
$91.35 |
| 82550 |
|
64 |
50 |
$91.16 |
| 80061 |
Lipid panel |
12 |
12 |
$64.35 |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
32 |
26 |
$53.11 |
| 84439 |
|
14 |
12 |
$51.12 |
| 84702 |
|
124 |
115 |
$35.43 |
| J1170 |
Injection, hydromorphone, up to 4 mg |
507 |
338 |
$22.03 |
| 96376 |
|
13 |
12 |
$19.88 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
605 |
419 |
$19.58 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
157 |
122 |
$8.30 |
| J2060 |
Injection, lorazepam, 2 mg |
37 |
25 |
$4.50 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
126 |
113 |
$3.25 |
| S0119 |
Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) |
147 |
141 |
$1.25 |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
40 |
37 |
$1.25 |
| G1003 |
Clinical decision support mechanism medicalis, as defined by the medicare appropriate use criteria program |
14 |
12 |
$0.00 |
| 76000 |
|
39 |
37 |
$0.00 |
| J3475 |
Injection, magnesium sulfate, per 500 mg |
16 |
13 |
$0.00 |
| S0028 |
Injection, famotidine, 20 mg |
12 |
12 |
$0.00 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
29 |
25 |
$0.00 |
| A9270 |
Non-covered item or service |
311 |
66 |
$0.00 |
| J2704 |
Injection, propofol, 10 mg |
17 |
16 |
$0.00 |
| J0690 |
Injection, cefazolin sodium, 500 mg |
23 |
15 |
$0.00 |
| J3490 |
Unclassified drugs |
128 |
95 |
$0.00 |
| 94760 |
|
14 |
12 |
$0.00 |
| 87807 |
|
37 |
35 |
$0.00 |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
37 |
31 |
$0.00 |
| 70498 |
|
12 |
12 |
$0.00 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
15 |
12 |
$0.00 |